Summary
BaxHTN is a study designed to test the safety, tolerability and effectiveness of a new medication, baxdrostat 1mg or 2mg or placebo, in people with high blood pressure that is not well controlled despite a stable regimen of at least 2 antihypertensive agents (one of which is a diuretic).
Throughout the study, you will keep taking your regular blood pressure medication. You may need to stop taking certain medicines. The study doctor will discuss this with you in detail.
Inclusion Criteria
- Male or female participants must be ≥ 18 years old
- Mean systolic blood pressure at screening visit in clinic ≥ 140 mmHg and < 170 mmHg
- Stable regimen of at least 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic)
Exclusion Criteria
- Mean systolic blood pressure at screening visit in clinic ≥ 170 mmHg
- Mean diastolic blood pressure at screening visit in clinic ≥ 110 mmHg
- Secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing’s syndrome, aortic coarctation
- New York Heart Association functional heart failure class IV at Screening
- Persistent atrial fibrillation
Duration
This study will last either 7 or 14 months (depending on what treatment group you are in) and has 4 parts: screening, run-in, treatment and follow-up.
In total, you may have up to 18 visits as part of this study. These visits will last between 15 minutes and 2.5 hours, depending on the number of tests and assessments.
Further resources for this study
https://www.astrazenecaclinicaltrials.com/study/D6970C00002/
https://clinicaltrials.gov/study/NCT06034743?term=D6970C00002&rank=1
What to do next if you are interested in participating
If you are interested to find out more, and possibly participate, please fill in the screening form below for this study.
Alternatively, please call 07788130868 or email nhsnwl.baxhtn@nhs.net for further information.
Legal matters
By submitting the form above you agree for us to hold your personal data for the purposes of assessing your suitability for this study, or other similar studies, and also to hold the data during the period of a study that you participate in. Assessment of suitability for participation normally involves the collection of personal medical information. We may need to share this information with either your registered GP surgery. If you participate in a study we may be required to share personal medical information that is relevant to the study with the sponsor so that the effectiveness and outcome can be evaluated.
We take informed consent very seriously, and will discuss this with you in detail before you participate in any study. Informed consent means that you understand what the study is about, what is involved, potential risks, data collection, communication, and various other matters so that you have a complete view and have time to consider everything before agreeing to participate.